Akari Therapeutics Plc
AKTX evidence brief
What we can confirm
- BioSniper Score:
- 8.5 / 10
- Market Cap:
- $18.9M
- Lead Asset:
- aktx-101 (Preclinical)
What it means
What to watch
Prepared research question
What matters most for AKTX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · AKTX
Akari Therapeutics Plc (AKTX) is a pre-revenue oncology biotechnology company developing next-generation antibody-drug conjugates (ADCs) centered on novel payload biology, with its lead candidate AKTX-101 advancing toward Phase 1 clinical trials.
Key risk: No revenue and high accumulated deficit
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$18.9M
Cash Runway
—
Lead Asset
aktx-101 (Preclinical)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 5 pipeline candidates · 1 clinical trial for Akari Therapeutics Plc.
Akari Therapeutics Plc (AKTX) is a pre-revenue oncology biotechnology company developing next-generation antibody-drug conjugates (ADCs) centered on novel payload biology, with its lead candidate AKTX-101 advancing toward Phase 1 clinical trials.
- Akari is an oncology company developing next-generation ADCs designed around novel payload biology [sec_mda · as of 2026-03-30].
- Lead candidate AKTX-101 is advancing through IND-enabling activities toward a planned Phase 1 clinical trial initiation in mid-2027 [news · published 2026-08-13].
- As of June 30, 2026, the company reported cash & equivalents of $7.7M, net income of -$4.8M, and shareholders' equity of $18.6M [sec].
- The company has not generated any revenue to date and has an accumulated deficit of $264.5 million as of December 31, 2025 [sec_mda · as of 2026-03-30].
- Akari has a strategic research collaboration with Whitehawk Therapeutics to expand its PH1 platform into dual-payload ADCs [news · published 2026-08-13].
What works
- AKTX-101 has shown anti-tumor activity in multiple clinically relevant urothelial cancer preclinical models, and compelling ASCO 2026 preclinical data further differentiates its PH1 mechanism in KRAS-mutated pancreatic cancer models [news · published 2026-08-13][news · published 2026-08-18].
- The company strengthened its balance sheet with approximately $8.6 million of financing during the second quarter of 2026, led by long-term strategic investors [news · published 2026-08-13].
- A strategic research collaboration with Whitehawk Therapeutics expands the potential application of Akari’s PH1 platform into dual-payload ADCs [news · published 2026-08-13].
What to weigh
- Akari has not initiated clinical studies for any programs in its active pipeline and has not commercialized any products; it may be years before a product candidate is commercialized, if ever [sec · filed 2026-07-10].
- The company has not generated any revenue to date and has an accumulated deficit of $264.5 million as of December 31, 2025 [sec_mda · as of 2026-03-30].
- Preclinical studies or clinical trials may be prolonged or delayed, potentially preventing timely regulatory approvals or commercialization [sec · filed 2026-07-10].
- The company has substantial operating losses expected to continue for the foreseeable future [sec_mda · as of 2026-03-30].
From the filings
Quoted directly from source documents.
Akari is an oncology company developing next-generation ADCs designed around novel payload biology.
“We are an oncology company developing next generation ADCs designed around novel payload biology.”
SEC MD&A · March 30, 2026
AKTX-101 is advancing toward Phase 1 clinical trial initiation in mid-2027.
“AKTX-101 advancing through IND-enabling development activities toward planned initiation of Phase 1 clinical trial in mid-2027”
News · August 13, 2026
Akari has not initiated clinical studies for any programs in its active pipeline.
“We have not initiated clinical studies for any of the programs in our active pipeline or entered into any strategic partnerships regarding the continued development of our legacy pipeline assets.”
SEC filings · July 10, 2026
Catalyst timeline
- 2025-04-15 · Phase 2 start for EMP-01 in social anxiety disorder — A Phase 2a trial of EMP-01 for social anxiety disorder is listed as a catalyst, though this candidate is not part of the company's current ADC-focused pipeline.
Risks & what to watch (4)›
Key risks
- No revenue and high accumulated deficit — No revenue generated to date; accumulated deficit of $264.5M as of Dec 31, 2025 [sec_mda · as of 2026-03-30].
- Pre-revenue with no clinical trials initiated — No clinical studies started for active pipeline; commercialization may be years away, if ever [sec · filed 2026-07-10].
- Potential delays in clinical development — Preclinical or clinical delays could prevent timely regulatory approvals or commercialization [sec · filed 2026-07-10].
- Continued operating losses — R&D and G&A expenses expected to result in substantial operating losses for the foreseeable future [sec_mda · as of 2026-03-30].
What to watch
- Initiation of Phase 1 clinical trial for AKTX-101, planned for mid-2027 [news · published 2026-08-13].
- Progress of the strategic collaboration with Whitehawk Therapeutics on dual-payload ADCs [news · published 2026-08-13].
- Further preclinical data updates for AKTX-101, particularly in KRAS-mutated pancreatic cancer and urothelial cancer models [news · published 2026-08-13][news · published 2026-08-18].
- Cash runway and any additional financing rounds, given the $7.7M cash position as of June 30, 2026 [sec].
Sources: Catalysts · News · Pipeline · SEC filings · SEC MD&A · Generated October 13, 2026 · How we verify sources →
Run Akari Therapeutics Plc through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Akari Therapeutics Plc facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 1.08 · 0% dilution
Lead: Phase 3
5 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
6
Total value held
$307K
| Holder | Shares | Value |
|---|---|---|
| armistice capital, llc | 38,922 | $200K |
| cresset asset management, llc | 20,561 | $106K |
| ifp advisors, inc | 181 | $932 |
| sbi securities co., ltd. | 5 | $26 |
| morgan stanley | 1 | $5 |
| truvestments capital llc | 1 | $5 |
Short Interest
as of Apr 21, 2026- % of float
- 1.8%
- Days to cover
- 0.5
- Shares short
- 5,810
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
AKTX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Akari Therapeutics Plc?
Akari Therapeutics Plc (AKTX) is a pre-revenue oncology biotechnology company developing next-generation antibody-drug conjugates (ADCs) centered on novel payload biology, with its lead candidate AKTX-101 advancing toward Phase 1 clinical trials.
What is Akari Therapeutics Plc's lead drug candidate?
Akari Therapeutics Plc's most advanced tracked candidate is aktx-101 (Preclinical) for Solid tumors (including lung, breast, urothelial, gastric, pancreatic, and others).
Who is the CEO of Akari Therapeutics Plc?
Mr. Abizer Gaslightwala is the chief executive officer of Akari Therapeutics Plc (AKTX).
Where is Akari Therapeutics Plc headquartered?
Akari Therapeutics Plc (AKTX) is headquartered in Tampa, FL, United States.
What therapeutic areas does Akari Therapeutics Plc focus on?
Akari Therapeutics Plc develops therapies across Oncology, Neurology, Hematology, Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.